Microscopic Polyangiitis (MPA) - Pipeline Review, H1 2019

Global Markets Direct’s, ‘Microscopic Polyangiitis (MPA) - Pipeline Review, H1 2019’, provides an overview of the Microscopic Polyangiitis (MPA) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Microscopic Polyangiitis (MPA), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Microscopic Polyangiitis (MPA) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Microscopic Polyangiitis (MPA)

- The report reviews pipeline therapeutics for Microscopic Polyangiitis (MPA) by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Microscopic Polyangiitis (MPA) therapeutics and enlists all their major and minor projects

- The report assesses Microscopic Polyangiitis (MPA) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Microscopic Polyangiitis (MPA)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Microscopic Polyangiitis (MPA)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Microscopic Polyangiitis (MPA) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Celltrion Inc

ChemoCentryx Inc

InflaRx NV

Teijin Pharma Ltd

Celltrion Inc

ChemoCentryx Inc

InflaRx NV

Teijin Pharma Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Microscopic Polyangiitis (MPA) - Overview

Microscopic Polyangiitis (MPA) - Therapeutics Development

Pipeline ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Microscopic Polyangiitis (MPA) - Overview

Microscopic Polyangiitis (MPA) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Microscopic Polyangiitis (MPA) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Microscopic Polyangiitis (MPA) - Companies Involved in Therapeutics Development

Celltrion Inc

ChemoCentryx Inc

InflaRx NV

Teijin Pharma Ltd

Microscopic Polyangiitis (MPA) - Drug Profiles

avacopan - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IFX-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

immune globulin (human) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rituximab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rituximab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Microscopic Polyangiitis (MPA) - Dormant Projects

Microscopic Polyangiitis (MPA) - Discontinued Products

Microscopic Polyangiitis (MPA) - Product Development Milestones

Featured News & Press Releases

May 18, 2017: Celltrion Healthcare Hungary Receives CHMP Positive Opinion for Blitzima (rituximab)

Dec 15, 2016: Celltrion Healthcare Hungary Receives CHMP Positive Opinion for Truxima

Dec 04, 2014: ChemoCentryx Granted EU Orphan Drug Designation for CCX168, an Orally Administered Complement C5a Receptor Inhibitor, for the Treatment of Microscopic Polyangiitis and Granulomatosis With Polyangiitis, Two Forms of ANCA-Associated Vasculitis

Jun 03, 2014: ChemoCentryx's CCX168, an Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation in ANCA-Associated Diseases by the FDA

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Microscopic Polyangiitis (MPA), H1 2019

Number of Products under Development by Companies, H1 2019

Products under ...

List of Tables

Number of Products under Development for Microscopic Polyangiitis (MPA), H1 2019

Number of Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Microscopic Polyangiitis (MPA) - Pipeline by Celltrion Inc, H1 2019

Microscopic Polyangiitis (MPA) - Pipeline by ChemoCentryx Inc, H1 2019

Microscopic Polyangiitis (MPA) - Pipeline by InflaRx NV, H1 2019

Microscopic Polyangiitis (MPA) - Pipeline by Teijin Pharma Ltd, H1 2019

Microscopic Polyangiitis (MPA) - Dormant Projects, H1 2019

Microscopic Polyangiitis (MPA) - Discontinued Products, H1 2019

List of Figures

List of Figures

Number of Products under Development for Microscopic Polyangiitis (MPA), H1 2019 6

Number of Products under Development by Companies, H1 2019 7 ...

List of Figures

Number of Products under Development for Microscopic Polyangiitis (MPA), H1 2019 6

Number of Products under Development by Companies, H1 2019 7

Number of Products by Top 10 Targets, H1 2019 9

Number of Products by Stage and Targets, H1 2019 9

Number of Products by Mechanism of Actions, H1 2019 11

Number of Products by Stage and Mechanism of Actions, H1 2019 11

Number of Products by Routes of Administration, H1 2019 13

Number of Products by Stage and Routes of Administration, H1 2019 13

Number of Products by Molecule Types, H1 2019 15

Number of Products by Stage and Molecule Types, H1 2019 15

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports